OA
INSIDER · 3 COMPANIES · DIRECTOR
ORBIMED ADVISORS LLC
Every open-market transaction filed under this name, Sep 21 to Nov 5. The same name appears at more than one issuer; filings don’t say whether it’s one person.
Filings
16
16 buys · 0 sells
Bought
$54.8M
open market, at cost
Sold
—
includes scheduled sales
Buys since
−6.6%
avg move from buy price, 13 priced
Filings
| Traded | Ticker | Company | Role | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|---|---|
| Nov 5 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 125,200 | $7.31 | $915K | +6.7% |
| Nov 5 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 30,891 | $7.31 | $226K | +6.7% |
| Nov 4 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 20,000 | $7.07 | $141K | +10.3% |
| Nov 4 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 5,000 | $7.07 | $35K | +10.3% |
| Nov 4 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 37,100 | $7.78 | $289K | +0.3% |
| Nov 4 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 9,267 | $7.78 | $72K | +0.3% |
| Nov 3 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 98,600 | $7.88 | $777K | −1.0% |
| Nov 3 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 24,400 | $7.88 | $192K | −1.0% |
| Nov 3 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 97,800 | $7.84 | $767K | −0.5% |
| Nov 3 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 24,313 | $7.84 | $191K | −0.5% |
| Nov 2 | ASPE | Aspen Neuroscience, Inc. | Director | Buy | 1,000,000 | $15.00 | $15M | −21.6% |
| Sep 28 | ADRX | ADARx Pharmaceuticals, Inc. | Director | Buy | 588,235 | $17.00 | $10M | — |
| Sep 28 | ADRX | ADARx Pharmaceuticals, Inc. | Director | Buy | 61,516 | $17.00 | $1M | — |
| Sep 28 | ADRX | ADARx Pharmaceuticals, Inc. | Director | Buy | 300,249 | $17.00 | $5.1M | — |
| Sep 21 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 1,000,000 | $15.00 | $15M | −48.0% |
| Sep 21 | ETRA | Electra Therapeutics, Inc. | Director | Buy | 333,333 | $15.00 | $5M | −48.0% |
"Since" is the stock's move from the filed price to the latest quote on file, not a scored call. Open-market purchases and sales only; option exercises and grants are excluded.